Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models

References

• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916–1924.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–2266.
   PubMed Web of Science ®Google Scholar
• Dulisse B, Li X, Gayle JA, et al. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ. 2013;16:720–735.
   PubMedGoogle Scholar
• Hill G, Barron R, Fust K, et al. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses. J Med Econ. 2014;17:32–42.
   PubMedGoogle Scholar
• Fust K, Li X, Maschio M, et al. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. Gynecol Oncol. 2014;133:446–453.
   PubMed Web of Science ®Google Scholar
• Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–237.
   PubMed Web of Science ®Google Scholar
• United States Department of Health & Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE); 2009 May 28, (v4.03: June 14, 2010). http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf.
   Google Scholar
• Neulasta® Prescribing Information. [revised 2011 6]. Amgen Inc. Patent: http://pat.amgen.com/neulasta/
   Google Scholar
• NEUPOGEN® Prescribing Information; v25 [revised 2014 2]. Amgen Manufacturing, Limited, a subsidiary of Amgen Inc.
   Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164–170.
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178–1184.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (Oxford, England: 1990). 2011;47:8–32.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199–3212.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology (NCCN Guidelines): Myeloid Growth Factors v1; 2015 [cited 2015 Jun 30]. http://www.NCCN.org.
   Google Scholar
• Whyte S, Cooper KL, Stevenson MD, et al. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Value Health. 2011;14:465–474.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health. 2009;12:217–225.
   PubMed Web of Science ®Google Scholar
• Danova M, Chiroli S, Rosti G, et al. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori. 2009;95:219–226.
   PubMed Web of Science ®Google Scholar
• Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol. 2005;23:6639–6646.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol. 2011;77:221–240.
   PubMed Web of Science ®Google Scholar
• Esser M, Brunner H. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics. 2003;21:1295–1313.
   PubMed Web of Science ®Google Scholar
• Uyl-De Groot CA, Huijgens PC, Rutten FF. Colony-stimulating factors and peripheral blood progenitor cell transplantation. Benefits and costs. Pharmacoeconomics. 1996;10:23–35.
   PubMed Web of Science ®Google Scholar
• Hirsch BR, Lyman GH. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics. 2012;30:497–511.
   PubMed Web of Science ®Google Scholar
• Barnes G, Pathak A, Schwartzberg L. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review. Adv Ther. 2014;31:683–695.
   PubMed Web of Science ®Google Scholar
• Kansara R, Kumar R, Seftel M. Is primary prophylaxis with granulocyte colony stimulating factor (G-CSF) indicated in the treatment of lymphoma? Transfus Apheresis Sci. 2013;49:51–55.
   PubMed Web of Science ®Google Scholar
• Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J Natl Compr Cancer Netw. 2015;13:e1–7.
   PubMed Web of Science ®Google Scholar
• Becker R, Dembek C, White LA, et al. The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature. Expert Rev Pharmacoecon Outcomes Res. 2012;12:775–793.
   PubMed Web of Science ®Google Scholar
• Rofail P, Tadros M, Ywakim R, et al. Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia. Expert Rev Pharmacoecon Outcomes Res. 2012;12:699–709.
   PubMed Web of Science ®Google Scholar
• Younis T, Rayson D, Jovanovic S, et al. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review. Breast Cancer Res Treat. 2016 Oct;159:425–432.
   PubMed Web of Science ®Google Scholar
• Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Cancer Netw. 2005;3:557–571.
   PubMedGoogle Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205.
   PubMed Web of Science ®Google Scholar
• Skedgel C, Rayson D, Younis T. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer? Supportive Care Cancer. 2016;24:387–394.
   PubMed Web of Science ®Google Scholar
• Eldar-Lissai A, Cosler LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008;11:172–179.
   PubMed Web of Science ®Google Scholar
• Cosler LE, Sivasubramaniam V, Agboola O, et al. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health. 2005;8:47–52.
   PubMed Web of Science ®Google Scholar
• Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24:2991–2997.
   PubMed Web of Science ®Google Scholar
• Timmer-Bonte JN, Adang EM, Termeer E, et al. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol. 2008;26:290–296.
   PubMed Web of Science ®Google Scholar
• Aarts MJ, Grutters JP, Peters FP, et al. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol. 2013;31:4283–4289.
   PubMed Web of Science ®Google Scholar
• Graczyk J, Cheung MC, Buckstein R, et al. Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis. Leuk Lymphoma. 2014;55:56–62.
   PubMed Web of Science ®Google Scholar
• Numnum TM, Kimball KJ, Rocconi RP, et al. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma–a cost-effectiveness analysis. Int J Gynecol Cancer. 2007;17:1019–1024.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lalla A, Barron RL, et al. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clinical Therapeutics. 2009;31:1092–1104.
   PubMed Web of Science ®Google Scholar
• Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009;25:401–411.
   PubMed Web of Science ®Google Scholar
• Liu Z, Doan QV, Malin J, et al. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy. 2009;7:193–205.
   PubMedGoogle Scholar
• Chan KK, Siu E, Krahn MD, et al. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J Clin Oncol. 2012;30:1064–1071.
   PubMed Web of Science ®Google Scholar
• Lathia N, Isogai PK, De Angelis C, et al. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. J Natl Cancer Inst. 2013;105:1078–1085.
   PubMedGoogle Scholar
• Lee EK, Wong WW, Trudeau ME, et al. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. Breast Cancer Res Treat. 2015;150:169–180.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute/Surveillance, Epidemiology, and End Results (SEER) database (SEER*Stat 6.5.1). Kaplan-Meier Method, Survival Sessions, No adjustment for heterogeneity. https://seer.cancer.gov/seerstat/software/
   Google Scholar
• Cancer Research UK. CancerStats Factsheet, Breast Cancer, March 2007. Available from: http://publications.cancerresearchuk.org/WebRoot/crukstoredb/CRUK_PDFs/CSFSBREAST.pdf.
   Google Scholar
• Arias E. United States life tables, 2002. Natl Vital Stat Rep. 2004 Nov 10;53(6):1–38.
   Google Scholar
• Office for National Statistics UK. Long-term Breast Cancer Survival,England and Wales, up to 2003. Available from: http://www.statistics.gov.uk/statbase/ssdataset.asp?vlnk9132&MoreY; 2005.
   Google Scholar
• Statistics Canada. Life Tables, Canada, Provinces and Territories, 2009 to 2011. http://www.statcan.gc.ca/pub/84-537-x/84-537-x2013005-eng.pdf.
   Google Scholar
• Timmer-Bonte J, De Boo T, Smit H, et al. Prevention of chemotherapyinduced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol. 2005;23:7974–7984.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Kummel S, Du Bois A, et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292–298.
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, Van Der Holt B, Van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21:3041–3050.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD003189.
   Google Scholar
• Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2001;2:47–56.
   PubMedGoogle Scholar
• Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol. 1998;16:2352–2358.
   PubMed Web of Science ®Google Scholar
• Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003;101:3840–3848.
   PubMed Web of Science ®Google Scholar
• Chrischilles E, Delgado DJ, Stolshek BS, et al. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin’s lymphoma. Cancer Control. 2002;9:203–211.
   PubMedGoogle Scholar
• Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Cancer Netw. 2008;6:109–118.
   PubMedGoogle Scholar
• Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44:2069–2076.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale D, Chen H, et al. Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy (abstract 1571). Proc Am Soc Clin Oncol. 2001;20:394A.
   Google Scholar
• Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40:402–407.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427–437.
   PubMed Web of Science ®Google Scholar
• Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol. 2006;17:1205–1212.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony stimulating factors (G-CSF) on mortality and febrile neutropenia in adult cancer patients receiving chemotherapy; a systematic review and meta-analysis. J Clin Oncol. 2007;25:3158–3167.
   PubMed Web of Science ®Google Scholar
• Siena S, Piccart MJ, Holmes FA, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003;10:715–724.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003;98:2402–2409.
   PubMed Web of Science ®Google Scholar
• Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23:2283–2295.
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21:968–975.
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncology. 2003;14:29–35.
   PubMed Web of Science ®Google Scholar
• Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727–731.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524–4531.
   PubMed Web of Science ®Google Scholar
• Shayne M, Crawford J, Dc D, et al.; Group ANCS. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100:255–262.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Moliterni A, Zambetti M, et al. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. Bmj. 2005;330:217.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Li S, Gelber RD, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet. 2005;366:1108–1110.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901–906.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304:10–15.
   PubMed Web of Science ®Google Scholar
• Leonard RC, Miles D, Thomas R, et al.; Group UKBCNA. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer. 2003;89:2062–2068.
   PubMed Web of Science ®Google Scholar
• Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87:277–283.
   PubMed Web of Science ®Google Scholar
• Pettengell RBASTDea. INC-EU Prospective observational European neutropenia study: preliminary Hodgkin and non-Hodgkin lymphoma results. In: Abstract 284. 11th Congress of the European Hematology Association; 2006 Jun 15–18; Amsterdam, The Netherlands; 2006. ISSN 0390-6078.
   Google Scholar
• Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Supportive Care Cancer. 2008;16:1299–1309.
   PubMed Web of Science ®Google Scholar
• Hanna RK, Poniewierski MS, Laskey RA, et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2013;129:74–80.
   PubMed Web of Science ®Google Scholar
• Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anti-Cancer Drugs. 1998;9:899–907.
   PubMed Web of Science ®Google Scholar
• Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics. 2001;19:1091–1102.
   PubMed Web of Science ®Google Scholar
• Lathia N Evaluation of direct medical cost, lost productivity, health utility and quality of life in patients hospitalized for febrile neutropenia [dissertation]. Toronto (Canada): University of Toronto; 2008
   Google Scholar
• Havrilesky LJ, Broadwater G, Davis DM, et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol. 2009;113:216–220.
   PubMed Web of Science ®Google Scholar
• Launois R, Reboul-Marty J, Henry B, et al. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics. 1996;10:504–521.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Crawford J, Tomita D, et al. Changing patterns of chemotherapy relative dose intensity and supportive care for aggressiveB-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2016;57(2):283-290.
   Google Scholar
• Lyman GH, Dale DC, Tomita D, et al. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res Treat. 2013;139:863–872.
   PubMed Web of Science ®Google Scholar